Beyond spasticity reduction: botulinum toxin-a injection is associated with changes in abnormal flexor synergies of the upper limb in chronic stroke
DOI:
https://doi.org/10.2340/jrm.v58.44906Keywords:
Stroke, Upper extremity, Spasticity, Botulinum Toxin, RehabilitationAbstract
Objective: This study aimed to investigate the association between botulinum toxin type A treatment and changes in spasticity and abnormal flexor synergies in patients with chronic stroke.
Subjects: Twenty-eight patients with chronic stroke (mean age 56.5 years; mean time since onset 6.3 years) who received botulinum toxin type A injections into upper-arm flexor muscles (biceps brachii, brachialis, or brachioradialis) were enrolled.
Methods: This was a retrospective, single-centre cohort study. Assessments were performed before and approximately 2 months after injection. Primary outcomes were changes in spasticity measured by the Modified Ashworth Scale and the abnormal flexor synergy index based on kinematic analysis. Secondary outcomes included changes in voluntary shoulder flexion angle and subgroup analyses according to baseline upper extremity motor severity and responder/non-responder status based on changes in the Modified Ashworth Scale scores of the elbow flexors.
Results: Generalized estimating equation analyses showed significant changes in Modified Ashworth Scale elbow flexor scores and the abnormal flexor synergy index after injection. In severity-stratified analyses, significant Time × Severity interactions were observed for Modified Ashworth Scale scores of the elbow and wrist flexors, whereas no significant interaction was found for the abnormal flexor synergy index. In responder/non-responder analyses, a significant Time × Responder-status interaction was observed for the abnormal flexor synergy index. Non-responders showed no significant changes in Modified Ashworth Scale scores or the abnormal flexor synergy index and showed reduced maximum voluntary shoulder flexion angle.
Conclusion: This study suggests that botulinum toxin type A treatment was associated with changes in abnormal flexor synergies, in addition to reducing muscle tone. These findings highlight the value of incorporating kinematic assessments such as the abnormal flexor synergy index into the clinical evaluation of botulinum toxin treatment.
Downloads
References
Li S, Francisco GE, Rymer WZ. A new definition of poststroke spasticity and the interference of spasticity with motor recovery from acute to chronic stages. Neurorehabil Neural Repair 2021; 35: 601–610.
https://doi.org/10.1177/15459683211011214 DOI: https://doi.org/10.1177/15459683211011214
Zeng H, Chen J, Guo Y, Tan S. Prevalence and risk factors for spasticity after stroke: a systematic review and meta-analysis. Front Neurol 2021; 11: 616097.
https://doi.org/10.3389/fneur.2020.616097 DOI: https://doi.org/10.3389/fneur.2020.616097
Pundik S, McCabe J, Skelly M, Tatsuoka C, Daly JJ. Association of spasticity and motor dysfunction in chronic stroke. Ann Phys Rehabil Med 2019; 62: 397–402.
https://doi.org/10.1016/j.rehab.2018.07.006 DOI: https://doi.org/10.1016/j.rehab.2018.07.006
Zorowitz RD, Gillard PJ, Brainin M. Poststroke spasticity: sequelae and burden on stroke survivors and caregivers. Neurology 2013; 80(Suppl 2): S45–S52.
https://doi.org/10.1212/WNL.0b013e3182764c86 DOI: https://doi.org/10.1212/WNL.0b013e3182764c86
Lundström E, Smits A, Borg J, Terént A. Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event. Stroke 2010; 41: 319–324.
https://doi.org/10.1161/STROKEAHA.109.558619 DOI: https://doi.org/10.1161/STROKEAHA.109.558619
Li S, Chen YT, Francisco GE, Zhou P, Rymer WZ. A unifying pathophysiological account for post-stroke spasticity and disordered motor control. Front Neurol 2019; 10: 468.
https://doi.org/10.3389/fneur.2019.00468 DOI: https://doi.org/10.3389/fneur.2019.00468
Sunnerhagen KS, Opheim A, Alt Murphy M. Onset, time course and prediction of spasticity after stroke or traumatic brain injury. Ann Phys Rehabil Med 2019; 62: 431–434.
https://doi.org/10.1016/j.rehab.2018.04.004 DOI: https://doi.org/10.1016/j.rehab.2018.04.004
Dong Y, Wu T, Hu X, Wang T. Efficacy and safety of botulinum toxin type A for upper limb spasticity after stroke or traumatic brain injury: a systematic review with meta-analysis and trial sequential analysis. Eur J Phys Rehabil Med 2017; 53: 256–267.
https://doi.org/10.23736/S1973-9087.16.04329-X DOI: https://doi.org/10.23736/S1973-9087.16.04329-X
Shaw LC, Price CI, van Wijck FM, Shackley P, Steen N, Barnes MP, et al. Botulinum Toxin for the Upper Limb after Stroke (BoTULS) Trial: effect on impairment, activity limitation, and pain. Stroke 2011; 42: 1371–1379.
https://doi.org/10.1161/STROKEAHA.110.582197 DOI: https://doi.org/10.1161/STROKEAHA.110.582197
Cameron ID, Ada L, Crotty M, Palit M, Huang L, Olver J, et al. The lack of effect of botulinum toxin-A on upper limb activity in chronic stroke: a short report from the InTENSE Trial. Toxins (Basel) 2024; 16: 510.
https://doi.org/10.3390/toxins16120510 DOI: https://doi.org/10.3390/toxins16120510
Pandyan AD, Vuadens P, van Wijck FM, Stark S, Johnson GR, Barnes MP. Are we underestimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002; 16: 654–660.
https://doi.org/10.1191/0269215502cr536oa DOI: https://doi.org/10.1191/0269215502cr536oa
Albani G, Cimolin V, Galli M, Vimercati S, Bar D, Campanelli L, et al. Use of surface EMG for evaluation of upper limb spasticity during botulinum toxin therapy in stroke patients. Funct Neurol 2010; 25: 103–107.
Alvisi E, Serrao M, Conte C, Alfonsi E, Tassorelli C, Prunetti P, et al. Botulinum toxin A modifies nociceptive withdrawal reflex in subacute stroke patients. Brain Behav 2018; 8: e01069. DOI: https://doi.org/10.1002/brb3.1162
https://doi.org/10.1002/brb3.1069 DOI: https://doi.org/10.1002/brb3.1069
Bensmail D, Robertson JV, Fermanian C, Roby-Brami A. Botulinum toxin to treat upper-limb spasticity in hemiparetic patients: analysis of function and kinematics of reaching movements. Neurorehabil Neural Repair 2010; 24: 273–281.
https://doi.org/10.1177/1545968309347682 DOI: https://doi.org/10.1177/1545968309347682
Fridman EA, Crespo M, Gomez Argüello S, Degue L, Villarreal M, Bohlhalter S, et al. Kinematic improvement following Botulinum Toxin-A injection in upper-limb spasticity due to stroke. J Neurol Neurosurg Psychiatry 2010; 81: 423–427.
https://doi.org/10.1136/jnnp.2009.188052 DOI: https://doi.org/10.1136/jnnp.2009.188052
McMorland AJ, Runnalls KD, Byblow WD. A neuroanatomical framework for upper limb synergies after stroke. Front Hum Neurosci 2015; 9: 82.
https://doi.org/10.3389/fnhum.2015.00082 DOI: https://doi.org/10.3389/fnhum.2015.00082
Zackowski KM, Dromerick AW, Sahrmann SA, Thach WT, Bastian AJ. How do strength, sensation, spasticity and joint individuation relate to the reaching deficits of people with chronic hemiparesis? Brain 2004; 127: 1035–1046.
https://doi.org/10.1093/brain/awh116 DOI: https://doi.org/10.1093/brain/awh116
Schieber MH, Poliakov AV. Partial inactivation of the primary motor cortex hand area: effects on individuated finger movements. J Neurosci 1998; 18: 9038–9054.
https://doi.org/10.1523/JNEUROSCI.18-21-09038.1998 DOI: https://doi.org/10.1523/JNEUROSCI.18-21-09038.1998
Wang X, Fu Y, Ye B, Babineau J, Ding Y, Mihailidis A. Technology-based compensation assessment and detection of upper extremity activities of stroke survivors: systematic review. J Med Internet Res 2022; 24: e34307 DOI: https://doi.org/10.2196/34307
Dewald JP, Pope PS, Given JD, Buchanan TS, Rymer WZ. Abnormal muscle coactivation patterns during isometric torque generation at the elbow and shoulder in hemiparetic subjects. Brain 1995; 118: 495–510.
https://doi.org/10.1093/brain/118.2.495 DOI: https://doi.org/10.1093/brain/118.2.495
Ellis MD, Schut I, Dewald JPA. Flexion synergy overshadows flexor spasticity during reaching in chronic moderate to severe hemiparetic stroke. Clin Neurophysiol 2017; 128: 1308–1314.
https://doi.org/10.1016/j.clinph.2017.04.028 DOI: https://doi.org/10.1016/j.clinph.2017.04.028
Sukal TM, Ellis MD, Dewald JP. Shoulder abduction-induced reductions in reaching work area following hemiparetic stroke: neuroscientific implications. Exp Brain Res 2007; 183: 215–223.
https://doi.org/10.1007/s00221-007-1029-6 DOI: https://doi.org/10.1007/s00221-007-1029-6
Ohn SH, Yoo WK, Kim DY, Ahn S, Jung B, Choi I, et al. Measurement of synergy and spasticity during functional movement of the post-stoke hemiplegic upper limb. J Electromyogr Kinesiol 2013; 23: 501–507.
https://doi.org/10.1016/j.jelekin.2012.10.001 DOI: https://doi.org/10.1016/j.jelekin.2012.10.001
Grigoriu AI, Dinomais M, Rémy-Néris O, Brochard S. Impact of injection-guiding techniques on the effectiveness of botulinum toxin for the treatment of focal spasticity and dystonia: a systematic review. Arch Phys Med Rehabil 2015; 96: 2067–2078. e1.
https://doi.org/10.1016/j.apmr.2015.05.002 DOI: https://doi.org/10.1016/j.apmr.2015.05.002
Fugl-Meyer AR, Jääskö L, Leyman I, Olsson S, Steglind S. The post-stroke hemiplegic patient. 1. a method for evaluation of physical performance. Scand J Rehabil Med 1975; 7: 13–31. DOI: https://doi.org/10.2340/1650197771331
Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987; 67: 206–207.
https://doi.org/10.1093/ptj/67.2.206 DOI: https://doi.org/10.1093/ptj/67.2.206
Mobini A, Behzadipour S, Saadat M. Test–retest reliability of Kinect’s measurements for the evaluation of upper body recovery of stroke patients. Biomed Eng Online 2015; 14: 75.
https://doi.org/10.1186/s12938-015-0070-0 DOI: https://doi.org/10.1186/s12938-015-0070-0
Albert JA, Owolabi V, Gebel A, Brahms CM, Granacher U, Arnrich B. Evaluation of the pose tracking performance of the Azure Kinect and Kinect v2 for gait analysis in comparison with a gold standard: a pilot study. Sensors (Basel) 2020; 20: 5104.
https://doi.org/10.3390/s20185104 DOI: https://doi.org/10.3390/s20185104
Ito D, Kawakami M, Hosoi Y, Kamimoto T, Yamada Y, Takemura R, et al. Development of a quantitative assessment for abnormal flexor synergy index in patients with stroke: a validity and responsiveness study. J Neuroeng Rehabil 2024; 21: 229.
https://doi.org/10.1186/s12984-024-01534-3 DOI: https://doi.org/10.1186/s12984-024-01534-3
Woodbury ML, Velozo CA, Richards LG, Duncan PW. Rasch analysis staging methodology to classify upper extremity movement impairment after stroke. Arch Phys Med Rehabil 2013; 94: 1527–1533.
https://doi.org/10.1016/j.apmr.2013.03.007 DOI: https://doi.org/10.1016/j.apmr.2013.03.007
Lagalla G, Danni M, Reiter F, Ceravolo MG, Provinciali L. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb. Am J Phys Med Rehabil 2000; 79: 377–384.
https://doi.org/10.1097/00002060-200007000-00010 DOI: https://doi.org/10.1097/00002060-200007000-00010
Hara T, Niimi M, Yamada N, Shimamoto Y, Masuda G, Hara H, et al. Prognosis prediction of the effect of botulinum toxin therapy and intensive rehabilitation on the upper arm function in post-stroke patients using hierarchical cluster analysis. Disabil Rehabil 2022; 44: 6815–6823.
https://doi.org/10.1080/09638288.2021.1977394 DOI: https://doi.org/10.1080/09638288.2021.1977394
Wissel J, Kivi A. Post-stroke spastic movement disorder and botulinum toxin A therapy: early detection and early injection. Ann Rehabil Med 2023; 47: 326–336.
https://doi.org/10.5535/arm.23108 DOI: https://doi.org/10.5535/arm.23108
Phadke CP, Balasubramanian CK, Holz A, Davidson C, Ismail F, Boulias C. Adverse clinical effects of botulinum toxin intramuscular injections for spasticity. Can J Neurol Sci 2016; 43: 298–310.
https://doi.org/10.1017/cjn.2015.314 DOI: https://doi.org/10.1017/cjn.2015.314
Mathevon L, Declemy A, Laffont I, Perennou D. Immunogenicity induced by botulinum toxin injections for limb spasticity: a systematic review. Ann Phys Rehabil Med 2019; 62: 241–251.
https://doi.org/10.1016/j.rehab.2019.03.004 DOI: https://doi.org/10.1016/j.rehab.2019.03.004
Albrecht P, Jansen A, Lee JI, Moll M, Ringelstein M, Rosenthal D, et al. High prevalence of neutralizing antibodies after long-term botulinum neurotoxin therapy. Neurology 2019; 92: e48–e54.
https://doi.org/10.1212/WNL.0000000000006688 DOI: https://doi.org/10.1212/WNL.0000000000006688
Naumann M, Boo LM, Ackerman AH, Gallagher CJ. Immunogenicity of botulinum toxins. J Neural Transm (Vienna) 2013; 120: 275–290.
https://doi.org/10.1007/s00702-012-0893-9. DOI: https://doi.org/10.1007/s00702-012-0893-9
Ryan AS, Dobrovolny CL, Smith GV, Silver KH, Macko RF. Hemiparetic muscle atrophy and increased intramuscular fat in stroke patients. Arch Phys Med Rehabil 2002; 83: 1703–1707.
https://doi.org/10.1053/apmr.2002.36399 DOI: https://doi.org/10.1053/apmr.2002.36399
Picelli A, Bonetti P, Fontana C, Barausse M, Dambruoso F, Gajofatto F, et al. Is spastic muscle echo intensity related to the response to botulinum toxin type A in patients with stroke? A cohort study. Arch Phys Med Rehabil 2012; 93: 1253–1258.
https://doi.org/10.1016/j.apmr.2012.02.005 DOI: https://doi.org/10.1016/j.apmr.2012.02.005
Bensmail D, Hanschmann A, Wissel J. Satisfaction with botulinum toxin treatment in post-stroke spasticity: results from two cross-sectional surveys (patients and physicians). J Med Econ 2014; 17: 618–625.
https://doi.org/10.3111/13696998.2014.925462 DOI: https://doi.org/10.3111/13696998.2014.925462
Fheodoroff K, Rekand T, Medeiros L, Koßmehl P, Wissel J, Bensmail D, et al. Quality of life in subjects with upper- and lower-limb spasticity treated with incobotulinumtoxinA. Health Qual Life Outcomes 2020; 18: 51.
https://doi.org/10.1186/s12955-020-01304-4 DOI: https://doi.org/10.1186/s12955-020-01304-4
Francisco GE, Jost WH, Bavikatte G, Bandari DS, Tang SFT, Munin MC, et al. Individualized onabotulinumtoxinA treatment for upper limb spasticity resulted in high clinician- and patient-reported satisfaction: long-term observational results from the ASPIRE Study. PM R 2020; 12: 1120–1133.
https://doi.org/10.1002/pmrj.12328 DOI: https://doi.org/10.1002/pmrj.12328
Published
How to Cite
License
Copyright (c) 2026 Michiyuki Kawakami, Daisuke Ito, Ken Azuma, Takayuki Kamimoto, Arisa Kawabata, Tetsuya Tsuji
This work is licensed under a Creative Commons Attribution 4.0 International License.
All digitalized JRM contents is available freely online. The Foundation for Rehabilitation Medicine owns the copyright for all material published until volume 40 (2008), as from volume 41 (2009) authors retain copyright to their work and as from volume 49 (2017) the journal has been published Open Access, under CC-BY-NC licences (unless otherwise specified). The CC-BY-NC licenses allow third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
From 2024, articles are published under the CC-BY licence. This license permits sharing, adapting, and using the material for any purpose, including commercial use, with the condition of providing full attribution to the original publication.
